This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Zosuquidar
DrugBank Accession Number
DB06191
Background

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 527.616
Monoisotopic: 527.238433576
Chemical Formula
C32H31F2N3O2
Synonyms
  • Zosuquidar

Pharmacology

Indication

Investigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

P-glycoproteins are proteins which convert the energy derived from the hydrolysis of ATP to structural changes in protein molecules, in order to perform coupling, thus discharging medicine from cells. If P-glycoprotein coded with the MDR1 gene manifests itself in cancer cells, it discharges much of the antineoplastic drugs from the cells, making cancer cells medicine tolerant, and rendering antineoplastic drugs ineffective. This protein also manifests itself in normal organs not affected by the cancer (such as the liver, small intestine, and skin cells in blood vessels of the brain), and participates in the transportation of medicine. The compound Zosuquidar inhibits this P-glycoprotein, causing the cancer cells to lose their medicine tolerance, and making antineoplastic drugs effective.

TargetActionsOrganism
AP-glycoprotein 1
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Zosuquidar.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Zosuquidar.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Zosuquidar.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Zosuquidar.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Zosuquidar.
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Zosuquidar.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Zosuquidar.
Belantamab mafodotinThe serum concentration of Belantamab mafodotin can be increased when it is combined with Zosuquidar.
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Zosuquidar.
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Zosuquidar.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Zosuquidar trihydrochloride813AGY3126167465-36-3ZPFVQKPWGDRLHL-WITOOOCMSA-N

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
AB5K82X98Y
CAS number
167354-41-8
InChI Key
IHOVFYSQUDPMCN-DBEBIPAYSA-N
InChI
InChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m1/s1
IUPAC Name
(2R)-1-{4-[(2R,4S,11R)-3,3-difluorotetracyclo[10.4.0.0^{2,4}.0^{5,10}]hexadeca-1(16),5,7,9,12,14-hexaen-11-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol
SMILES
[H][C@]12C3=CC=CC=C3[C@H](N3CCN(C[C@@H](O)COC4=CC=CC5=C4C=CC=N5)CC3)C3=CC=CC=C3[C@@]1([H])C2(F)F

References

General References
Not Available
PubChem Compound
153997
ChemSpider
24599682
BindingDB
50420186
ChEMBL
CHEMBL444172
ZINC
ZINC000100029945
PDBe Ligand
ZQU
Wikipedia
Zosuquidar
PDB Entries
6fn1 / 6qee / 7a6f

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes (MDS)1
1, 2CompletedTreatmentMyeloid Leukemias2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00974 mg/mLALOGPS
logP5.17ALOGPS
logP4.82ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)7.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.83 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity146.68 m3·mol-1ChemAxon
Polarizability56.04 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8998
Blood Brain Barrier+0.9118
Caco-2 permeable-0.6096
P-glycoprotein substrateSubstrate0.8405
P-glycoprotein inhibitor IInhibitor0.8163
P-glycoprotein inhibitor IIInhibitor0.9785
Renal organic cation transporterNon-inhibitor0.51
CYP450 2C9 substrateNon-substrate0.7839
CYP450 2D6 substrateNon-substrate0.6365
CYP450 3A4 substrateSubstrate0.5488
CYP450 1A2 substrateInhibitor0.6444
CYP450 2C9 inhibitorNon-inhibitor0.6474
CYP450 2D6 inhibitorInhibitor0.5249
CYP450 2C19 inhibitorNon-inhibitor0.6238
CYP450 3A4 inhibitorNon-inhibitor0.7309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7929
Ames testNon AMES toxic0.638
CarcinogenicityNon-carcinogens0.9009
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7076 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8796
hERG inhibition (predictor II)Inhibitor0.9373
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Nies AT, Herrmann E, Brom M, Keppler D: Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):449-61. Epub 2007 Dec 19. [Article]
  2. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]

Drug created at March 19, 2008 16:16 / Updated at May 02, 2022 10:03